CTOs on the Move

Minaris Advanced Therapies

www.minaris.com

 
Minaris Regenerative Medicine is a global Contract Development and Manufacturing Organization (CDMO) with over 25 years of experience in cell and gene therapies. The company operates advanced facilities across North America, Europe, and Asia, providing comprehensive solutions for advanced therapy medicinal products (ATMPs). Minaris specializes in clinical and commercial manufacturing, process development, and technology transfer, ensuring compliance with regulatory standards in the U.S., EU, and Japan. The company offers a range of services, including GMP manufacturing for cell therapies, technology transfer, and clinical development support for Phase I-III trials. Minaris has successfully completed over 100 technology transfers and has recently commercialized ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.minaris.com
  • 400 Rouse Blvd
    Philadelphia, PA USA
  • Phone: +49 89 7009608

Executives

Name Title Contact Details
Luciana Mansolelli
 Chief Quality Officer Profile
Ilya Koltover
 Chief Transformation Officer Profile

Similar Companies

Sinclair Research Center Inc

Sinclair Research Center Inc is a Columbia, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tolerx

Tolerx is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Silverback Therapeutics

Silverback Therapeutics is charting a new path for treating a range of severe diseases. We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness — until now.

Stratos Genomics

Stratos Group is dedicated to the conversion of science and technology into commercial solutions for the advancement of mankind and the protection of the environment. Also under the Stratos Group umbrella is Stratos Product Development. Stratos Product Development is a world leader in innovation and high tech product development services.

PepGen

Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders.